  In health technology assessment, decisions are based on complex
cost-effectiveness models which, to be implemented, require numerous input
parameters. When some of relevant estimates are not available the model may
have to be simplified. Multi-parameter evidence synthesis allows to combine
data from diverse sources of evidence resulting in obtaining estimates required
in clinical decision-making that otherwise may not be available. We demonstrate
how bivariate meta-analysis (BVMA) can be used to predict unreported estimate
of a treatment effect enabling implementation of multi-state Markov model,
which otherwise needs to be simplified. To illustrate this, we used an example
of cost-effectiveness analysis for docetaxel in combination with prednisolone
in metastatic hormone-refractory prostate cancer (mHRPC). BVMA was used to
model jointly available data on treatment effects on overall survival (OS) and
progression-free survival (PFS) to predict the unreported effect on PFS in a
study evaluating docetaxel. Predicted treatment effect on PFS allowed
implementation of a three-state Markov model comprising of stable disease,
progressive disease and death states, whilst lack of the estimate restricted
the model to two-state model (stable disease and death states). The two-state
and three-state models were compared by calculating incremental
cost-effectiveness ratios, which was much lower in the three-state model:
{\pounds}21966 per QALY gained compared to {\pounds}30026 obtained from the
two-state model. In contrast to the two-state model, the three-state model has
the advantage of distinguishing patients who progressed from those who did not
progress. The use of advanced meta-analytic technique helped to obtain relevant
parameter estimate to populate a model which describes natural history more
accurately, and at the same helped to prevent valuable clinical data from being
discarded.
